Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
FK506 is a candidate drug for acute stroke. For such drugs, any decision to proceed to clinical trial should be based on a full and unbiased assessment of the animal data, and consideration should be given to the limitations of those data. Such an assessment should include not only the efficacy of a drug but also the in vivo characteristics and limits to that efficacy. Here we use systematic review and meta-analysis to assess the evidence for a protective effect of FK506 in animal models of stroke. In all, 29 studies were identified describing procedures involving 1759 animals. The point estimate for the effect of FK506 was a 31.3% (95% confidence interval 27.2% to 35.4%) improvement in outcome. Efficacy was higher with ketamine anaesthesia and temporary ischaemia and was lower in rats, in animals with comorbidities, and where outcome was measured as infarct size alone. Reported study quality was modest by clinical trial standards, and efficacy was lower in high-quality studies. These findings show a substantial efficacy for FK506 in experimental stroke, but raise concerns that our estimate of effect size might be too high because of factors such as study quality and possible publication bias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 1×
“Biological activities of FK506 include inhibition of calcineurin activity (Liu et al, 1991) and of neuronal apoptosis (Macleod et al, 2001), and efficacy in animal models of renal (Nalesnik et al, 1990), hepatic (Suzuki et al, 1993) and myocardial (Weinbrenner et al, 1998) ischaemia.”
BackgroundMoher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Emergency medicine animal research: does use of randomization and blinding affect the results?
Bebarta, V., Luyten, D., & Heard, K. (2003) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2003.tb00056.x · Cited by 244 · cited 1×
“Bebarta et al (2003) have shown that studies reporting randomisation and/ or blinding are less likely to report positive findings than those which do not; the extent to which such deficiencies in study design might have led to the overestimation of the effect of FK506 is not known.”
Background
Cited by
1,026 Experimental treatments in acute stroke
O'Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H., & Howells, D. W. (2006) · Annals of Neurology · doi:10.1002/ana.20741 · Cited by 1,460
Self-citationCan Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
“In a recent systematic review of studies testing the efficacy of interventions in animal models of human disease, only six reported testing for the presence of publication bias, and such bias was found in four [34,42–46].”
BackgroundSelf-citationUpdate of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Self-citationA call for transparent reporting to optimize the predictive value of preclinical research
Landis, S. C., Amara, S. G., Asadullah, K., Austin, C. P., Blumenstein, R., Bradley, E. W., Crystal, R. G., Darnell, R. B., Ferrante, R. J., Fillit, H., et al. (2012) · Nature · doi:10.1038/nature11556 · Cited by 1,196
Self-citationPublication bias in reports of animal stroke studies leads to major overstatement of efficacy
Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W., & Macleod, M. R. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000344 · Cited by 600
“FK506 [12] 27 96 1,596 32.”
MethodSelf-citationHow can we improve the pre-clinical development of drugs for stroke?
Sena, E., van der Worp, H. B., Howells, D., & Macleod, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.009 · Cited by 365
Self-citationWhy animal studies are often poor predictors of human reactions to exposure
Bracken, M. B. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.08k033 · Cited by 362
Risk of bias in reports of in vivo research: a focus for improvement
Macleod, M. R., Lawson McLean, A., Kyriakopoulou, A., Serghiou, S., de Wilde, A., Sherratt, N., Hirst, T., Hemblade, R., Bahor, Z., Nunes-Fonseca, C., et al. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002273 · Cited by 358
“Where risks of bias have been measured in systematic reviews of in vivo studies, a low prevalence of reporting of such measures has been found, and it is usual to find the largest reported efficacy in those studies meeting the lowest number of checklist items [3–7].”
BackgroundSelf-citationBench to Bedside: The Quest for Quality in Experimental Stroke Research
Dirnagl, U. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600298 · Cited by 349
Good Laboratory Practice: Preventing Introduction of Bias at the Bench
Macleod, M. R., Fisher, M., O'Collins, V., Sena, E. S., Dirnagl, U., Bath, P. M. W., Buchan, A., van der Worp, H. B., Traystman, R., Minematsu, K., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.525386 · Cited by 331
Self-citationHooijmans, C. R., Leenaars, M., & Ritskes-Hoitinga, M. (2010) · Alternatives to Laboratory Animals · doi:10.1177/026119291003800208 · Cited by 311
Howells, D. W., Porritt, M. J., Rewell, S. S., O'Collins, V., Sena, E. S., van der Worp, H. B., Traystman, R. J., & Macleod, M. R. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.66 · Cited by 309
Self-citationEvaluation of excess significance bias in animal studies of neurological diseases
Tsilidis, K. K., Panagiotou, O. A., Sena, E. S., Aretouli, E., Evangelou, E., Howells, D. W., Salman, R. A.-S., Macleod, M. R., & Ioannidis, J. P. A. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001609 · Cited by 295
“Lack of randomization, blinding, inadequate application of inclusion and exclusion criteria, inadequate statistical power, and inappropriate statistical analysis may compromise internal validity [6,7].”
BackgroundSelf-citationThe need for randomization in animal trials: an overview of systematic reviews
Hirst, J. A., Howick, J., Aronson, J. K., Roberts, N., Perera, R., Koshiaris, C., & Heneghan, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098856 · Cited by 294
“Twenty systematic reviews investigated treatments for experimental stroke, [17–20,24,28,32,36–47] four reviews investigated treatments for spinal cord diseases, [48–51] one review each investigated treatments for bone cancer, [52] intracerebral hemorrhage, [39] glioma, [53] multiple sclerosis, [54] Parkinson’s disease…”
BackgroundMeta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235
Preclinical research in Rett syndrome: setting the foundation for translational success
Katz, D. M., Berger-Sweeney, J. E., Eubanks, J. H., Justice, M. J., Neul, J. L., Pozzo-Miller, L., Blue, M. E., Christian, D., Crawley, J. N., Giustetto, M., et al. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.011007 · Cited by 206
Improving the translational hit of experimental treatments in multiple sclerosis
Vesterinen, H. M., Sena, E. S., ffrench-Constant, C., Williams, A., Chandran, S., & Macleod, M. R. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379612 · Cited by 182
Self-citationTranslating animal research into clinical benefit
Hackam, D. G. (2007) · BMJ · doi:10.1136/bmj.39104.362951.80 · Cited by 157
Ramirez, F. D., Motazedian, P., Jung, R. G., Di Santo, P., MacDonald, Z. D., Moreland, R., Simard, T., Clancy, A. A., Russo, J. J., Welch, V. A., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310628 · Cited by 138
Bringing rigour to translational medicine
Howells, D. W., Sena, E. S., & Macleod, M. R. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.232 · Cited by 130
Self-citationEvolution and Translation of Research Findings: From Bench to Where
Ioannidis, J. P. A. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010036 · Cited by 129
Potential Animal Models of Lacunar Stroke: A Systematic Review
Bailey, E. L., McCulloch, J., Sudlow, C., & Wardlaw, J. M. (2009) · Stroke · doi:10.1161/strokeaha.108.528430 · Cited by 128
Rozkalne, A., Hyman, B. T., & Spires-Jones, T. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.014 · Cited by 103
Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility
Knight, A. (2007) · Alternatives to Laboratory Animals · doi:10.1177/026119290703500610 · Cited by 105
The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results
Lyden, P. D., Bosetti, F., Diniz, M. A., Rogatko, A., Koenig, J. I., Lamb, J., Nagarkatti, K. A., Cabeen, R. P., Hess, D. C., Kamat, P. K., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.038047 · Cited by 73
Egan, K. J., Janssen, H., Sena, E. S., Longley, L., Speare, S., Howells, D. W., Spratt, N. J., Macleod, M. R., Mead, G. E., & Bernhardt, J. (2014) · Neurorehabilitation and Neural Repair · doi:10.1177/1545968314521694 · Cited by 49
Self-citationKrauth, D., Anglemyer, A., Philipps, R., & Bero, L. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001770 · Cited by 36
Zawadzka, M., Dabrowski, M., Gozdz, A., Szadujkis, B., Sliwa, M., Lipko, M., & Kaminska, B. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0925-9 · Cited by 34
Menke, J., Eckmann, P., Ozyurt, I. B., Roelandse, M., Anderson, N., Grethe, J., Gamst, A., & Bandrowski, A. (2022) · Journal of Medical Internet Research · doi:10.2196/37324 · Cited by 25
(2015) · PubMed Central · Cited by 20
Hunter, H., de Gracia Hahn, D., Duret, A., Im, Y. R., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2020) · eLife · doi:10.7554/elife.56573 · Cited by 12
Modeling Risk Factors and Confounding Effects in Stroke
McColl, B., Howells, D., Rothwell, N., & Denes, A. (2010) · Neuromethods · doi:10.1007/978-1-60761-750-1_9 · Cited by 3
Self-citation
Metadata
- Authors
- Macleod, M. R., O'Collins, T., Horky, L. L., Howells, D. W., & Donnan, G. A.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2005-06
- Volume
- 25
- Issue
- 6
- Pages
- 713-721
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2116952900
- Cited by
- 176
- References
- 6
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.